ReviewPediatric radiology2021
Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Review in Pediatric radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Advancing neuroimaging: novel manganese- and iron-based MRI contrast agents for cerebral ischemic diseases.Discover nano · 2025Review
- Highly accelerated 4D flow MRI with respiratory compensation and cardiac view sharing: a cross-sectional study of flow in the great vessels of pediatric congenital heart disease.Pediatric radiology · 2025Article
- Guidance for Pediatric Pituitary MRI Ordering: A Single Institution Improvement Initiative.AJNR. American journal of neuroradiology · 2024Article
- Biparametric MRI in prostate cancer during active surveillance: is it safe?European radiology · 2024Review
- Feasibility and Potential Diagnostic Value of Noncontrast Brain MRI in Nonsedated Children With Sturge-Weber Syndrome and Healthy Siblings.Journal of child neurology · 2024Article
- A case of severe anaphylactic reaction after administration of diagnostic-dose ferumoxytol in a pediatric patient.Pediatric radiology · 2024Article
- Graphene quantum dots for biosensing and bioimaging.RSC advances · 2024Review
- Molecular imaging of tumour-associated pathological biomarkers with smart nanoprobe: From "Seeing" to "Measuring".Exploration (Beijing, China) · 2023Review
- Comparison of 2D and 4D Flow MRI in Neonates Without General Anesthesia.Journal of magnetic resonance imaging : JMRI · 2023Article
- The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.Revista da Associacao Medica Brasileira (1992) · 2022Article
- Non-contrast magnetic resonance angiography/venography techniques: what are my options?Pediatric radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.
Indexed as
Identifiers
33871726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.